A model adapting the international CKD-PC risk score can accurately predict the individual-level kidney protection benefit from treatment with SGLT2 inhibitors in people with type 2 diabetes and no or early-stage CKD. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.